Literature DB >> 11159615

Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

N B Glazer, W W Cheatham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11159615      PMCID： PMC1119484     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.

Authors:  A J Krentz; C J Bailey; A Melander
Journal:  BMJ       Date:  2000-07-29

2.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Authors:  V Fonseca; J Rosenstock; R Patwardhan; A Salzman
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

3.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.

Authors:  C Ged; J M Rouillon; L Pichard; J Combalbert; N Bressot; P Bories; H Michel; P Beaune; P Maurel
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

4.  Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

Authors:  B H Wolffenbuttel; R Gomis; S Squatrito; N P Jones; R N Patwardhan
Journal:  Diabet Med       Date:  2000-01       Impact factor: 4.359
  4 in total
  4 in total

Review 1.  Pharmacokinetic interactions with thiazolidinediones.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2005-07       Impact factor: 5.606

4.  Inferences from targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model?

Authors:  Deepika Singhal; Deepak B Saxena
Journal:  Indian J Ophthalmol       Date:  2011 Sep-Oct       Impact factor: 1.848
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.